SG11202004230XA - Caffeic acid derivatives for treating hyperproliferative diseases - Google Patents
Caffeic acid derivatives for treating hyperproliferative diseasesInfo
- Publication number
- SG11202004230XA SG11202004230XA SG11202004230XA SG11202004230XA SG11202004230XA SG 11202004230X A SG11202004230X A SG 11202004230XA SG 11202004230X A SG11202004230X A SG 11202004230XA SG 11202004230X A SG11202004230X A SG 11202004230XA SG 11202004230X A SG11202004230X A SG 11202004230XA
- Authority
- SG
- Singapore
- Prior art keywords
- acid derivatives
- caffeic acid
- hyperproliferative diseases
- treating hyperproliferative
- treating
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584591P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/059975 WO2019094689A1 (en) | 2017-11-10 | 2018-11-09 | Caffeic acid derivatives for treating hyperproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004230XA true SG11202004230XA (en) | 2020-06-29 |
Family
ID=64664389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004230XA SG11202004230XA (en) | 2017-11-10 | 2018-11-09 | Caffeic acid derivatives for treating hyperproliferative diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10703721B2 (https=) |
| EP (1) | EP3707125A1 (https=) |
| JP (1) | JP7428642B2 (https=) |
| KR (1) | KR20200085815A (https=) |
| CN (1) | CN111417625A (https=) |
| AU (1) | AU2018366270B2 (https=) |
| BR (1) | BR112020009219A2 (https=) |
| CA (1) | CA3081975A1 (https=) |
| EA (1) | EA202091164A1 (https=) |
| MX (1) | MX2020004871A (https=) |
| SG (1) | SG11202004230XA (https=) |
| TW (1) | TWI846678B (https=) |
| UA (1) | UA126821C2 (https=) |
| WO (1) | WO2019094689A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539503B2 (en) | 2022-08-03 | 2026-02-03 | The University Of Toledo | Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| BRPI0709916B8 (pt) | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| NZ590372A (en) * | 2008-07-08 | 2012-09-28 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| EP2619184B1 (en) | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US9868736B2 (en) | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2015183987A1 (en) | 2014-05-27 | 2015-12-03 | Pharmakea, Inc. | Compositions and methods of delivery of deubiquitinase inhibitors |
| CA2948883A1 (en) * | 2014-06-02 | 2015-12-10 | Pharmakea, Inc. | Deubiquitinase inhibitors |
-
2018
- 2018-11-08 TW TW107139731A patent/TWI846678B/zh active
- 2018-11-09 KR KR1020207015972A patent/KR20200085815A/ko not_active Ceased
- 2018-11-09 US US16/185,669 patent/US10703721B2/en active Active
- 2018-11-09 EP EP18816306.7A patent/EP3707125A1/en active Pending
- 2018-11-09 JP JP2020525946A patent/JP7428642B2/ja active Active
- 2018-11-09 MX MX2020004871A patent/MX2020004871A/es unknown
- 2018-11-09 CA CA3081975A patent/CA3081975A1/en active Pending
- 2018-11-09 EA EA202091164A patent/EA202091164A1/ru unknown
- 2018-11-09 WO PCT/US2018/059975 patent/WO2019094689A1/en not_active Ceased
- 2018-11-09 UA UAA202003449A patent/UA126821C2/uk unknown
- 2018-11-09 SG SG11202004230XA patent/SG11202004230XA/en unknown
- 2018-11-09 AU AU2018366270A patent/AU2018366270B2/en not_active Ceased
- 2018-11-09 CN CN201880077894.0A patent/CN111417625A/zh active Pending
- 2018-11-09 BR BR112020009219-3A patent/BR112020009219A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019094689A1 (en) | 2019-05-16 |
| MX2020004871A (es) | 2020-08-06 |
| EP3707125A1 (en) | 2020-09-16 |
| JP2021502374A (ja) | 2021-01-28 |
| TWI846678B (zh) | 2024-07-01 |
| UA126821C2 (uk) | 2023-02-08 |
| CN111417625A (zh) | 2020-07-14 |
| AU2018366270A1 (en) | 2020-05-21 |
| KR20200085815A (ko) | 2020-07-15 |
| CA3081975A1 (en) | 2019-05-16 |
| AU2018366270B2 (en) | 2023-04-20 |
| TW201922707A (zh) | 2019-06-16 |
| US20190177276A1 (en) | 2019-06-13 |
| JP7428642B2 (ja) | 2024-02-06 |
| BR112020009219A2 (pt) | 2020-10-20 |
| EA202091164A1 (ru) | 2020-08-03 |
| US10703721B2 (en) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001244B (en) | Acid treatment for fertilizers to increase zinc solubility and availability | |
| IL259693A (en) | Preparations for topical administration and their use for the treatment of inflammation | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| LT3728271T (lt) | Makrocikliniai junginiai, skirti ligų gydymui | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL275002A (en) | Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| PT3109223T (pt) | Mistura para o tratamento de fertilizantes contendo ureia | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| PL3164394T3 (pl) | Inhibitory GLS1 do leczenia chorób | |
| IL251790B (en) | Compounds include thiazole for the treatment of culture diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| PL3506901T3 (pl) | Zastosowanie kwasu kynureninowego w leczeniu zaniku mięśni | |
| IL253847A0 (en) | Methods of treating diseases | |
| EP3268046A4 (en) | Conjugates for treating diseases | |
| PL3182980T3 (pl) | Leczenie chorób niedoboru glikozylacji | |
| ZA202102866B (en) | Glycyrrhetinic acid derivatives for treating hyperkalemia | |
| SG11202004230XA (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| IL274455A (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| HK40030457A (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| EP3261635A4 (en) | Compounds for treating ocular diseases | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| EP3354271A4 (en) | Agent for treating arthrological diseases | |
| GB201510658D0 (en) | Compositions for wound treatment |